{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:55:37Z","timestamp":1787028937003,"version":"build-2736575974"},"reference-count":103,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Measurable residual disease (MRD) has become a central determinant of prognosis and treatment planning in acute myeloid leukemia (AML). MRD assessment is now aided by a wide range of technologies, including next-generation sequencing, PCR-based assays, multiparameter flow cytometry, and emerging approaches such as liquid biopsy platforms and imaging-based detection. These modalities differ in sensitivity, applicability, and interpretive framework, yet each offers distinct advantages in specific disease contexts. Beyond technical issues, MRD is becoming increasingly integrated into clinical practice. In non-intensive treatment settings, where targeted and low-intensity regimens rely on dynamic disease monitoring to guide ongoing management, MRD is increasingly being used to inform therapeutic decisions. In the peri-transplant setting, MRD status influences conditioning strategies, donor selection, and the use of post-transplant interventions. Despite the growing evidence supporting the clinical relevance of MRD across these scenarios, challenges remain regarding standardization, optimal timing of assessment, and the interpretation of discordant results. This review summarizes the full landscape of MRD detection methods and examines the evolving role of MRD in contemporary AML management, emphasizing current applications and areas requiring further refinement.<\/jats:p>","DOI":"10.3390\/medsci14010123","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:31:14Z","timestamp":1772706674000},"page":"123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Landscape of Measurable Residual Disease in Acute Myeloid Leukemia: From Molecular Detection to Clinical Practice"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0587-5036","authenticated-orcid":false,"given":"Mohammad Shahzaib","family":"Qadir","sequence":"first","affiliation":[{"name":"Medical College, Aga Khan University, Karachi 74200, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","article-title":"Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia","volume":"14","author":"Aitken","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: A comprehensive review and 2016 update","volume":"6","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ajh.26503","article-title":"Classification of myeloid neoplasms\/acute leukemia: Global perspectives and the international consensus classification approach","volume":"97","author":"Arber","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Vonk, C.M., Al Hinai, A.S.A., Hanekamp, D., and Valk, P.J.M. (2021). Molecular minimal residual disease detection in acute myeloid leukemia. Cancers, 13.","DOI":"10.3390\/cancers13215431"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e390010","DOI":"10.1200\/EDBK_390010","article-title":"Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia","volume":"43","author":"Dekker","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of Measurable Residual Disease with Survival Outcomes in Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1038\/s41375-022-01692-0","article-title":"Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: A systematic review and meta-analysis","volume":"36","author":"Short","year":"2022","journal-title":"Leukemia"},{"key":"ref_10","first-page":"2813","article-title":"How I treat AML incorporating the updated classifications and guidelines","volume":"141","author":"Hourigan","year":"2023","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.22806","article-title":"Clonal evolution of acute myeloid leukemia from diagnosis to relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"Wei","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_17","first-page":"2300","article-title":"The mechanism of induction of complete remission in acute myeloblastic leukemia in man","volume":"29","author":"Hart","year":"1969","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/hematology.2023000454","article-title":"Understanding differential technologies for detection of MRD and how to incorporate into clinical practice","volume":"2023","author":"Cloos","year":"2023","journal-title":"Hematology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable residual disease as a biomarker in acute myeloid leukemia: Theoretical and practical considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2020.10.015","article-title":"Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies","volume":"83","author":"Walter","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cloos, J., Valk, P.J.M., Thiede, C., D\u00f6hner, K., Roboz, G.J., Wood, B.L., Walter, R.B., Wang, S.A., Wierzbowska, A., and Wei, A.H. (2026, February 09). 2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party, Blood, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/41397238\/.","DOI":"10.1182\/blood.2025031480"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ajh.25431","article-title":"Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance","volume":"94","author":"Sui","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/leu.2013.318","article-title":"What does MRD in leukemia really mean?","volume":"28","author":"Goldman","year":"2014","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41409-022-01794-4","article-title":"Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"57","author":"Orvain","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3324\/haematol.2022.281585","article-title":"Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia","volume":"108","author":"Orvain","year":"2023","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2018-12-852376","article-title":"Taking a \u201cbite out of all\u201d: Blinatumomab approval for MRD-positive ALL","volume":"133","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"Hemasphere"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.16362","article-title":"Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia","volume":"188","author":"Ghannam","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_33","first-page":"19","article-title":"Interpretation and analysis of the requirements of the standard EN ISO 15189: 2012","volume":"71","author":"Vassault","year":"2019","journal-title":"Ann. Biol. Clin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pathol.2019.09.021","article-title":"Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes","volume":"52","author":"Hanekamp","year":"2020","journal-title":"Pathology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41375-022-01647-5","article-title":"Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia","volume":"36","author":"Kramer","year":"2022","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1002\/cpcy.73","article-title":"Acute myeloid leukemia minimal residual disease detection: The difference from normal approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr. Protoc. Cytom."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/s41375-019-0393-0","article-title":"Peripheral blood minimal\/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia","volume":"33","author":"Lacombe","year":"2019","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood.2020006219","article-title":"Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow","volume":"137","author":"Godwin","year":"2021","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2016.44","article-title":"Harmonemia: A universal strategy for flow cytometry immunophenotyping\u2014A European LeukemiaNet WP10 study","volume":"30","author":"Lacombe","year":"2016","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34+CD38\u2212 leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","article-title":"Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission","volume":"21","author":"Moshaver","year":"2007","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2021014604","article-title":"An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: A prospective study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jtct.2023.12.030","article-title":"Optimal prognostic threshold for acute myeloid leukemia (AML) measurable residual disease (MRD) positivity by multiparameter flow cytometry: A report of 2051 patients from MRC\/NCRI, Gimema, HOVON, and Seattle","volume":"30","author":"Othus","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.27482","article-title":"Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development","volume":"100","author":"Short","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/10428199809057591","article-title":"Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR","volume":"31","author":"Tobal","year":"1998","journal-title":"Leuk. Lymphoma"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/hematology.2019000060","article-title":"MRD evaluation of AML in clinical practice: Are we there yet?","volume":"2019","author":"Freeman","year":"2019","journal-title":"Hematology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of Minimal Residual Disease in Standard-Risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): Results from the AML Study Group","volume":"134","author":"Agrawal","year":"2019","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1038\/s41375-018-0158-1","article-title":"Response kinetics and factors predicting survival in core-binding factor leukemia","volume":"32","author":"Boddu","year":"2018","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","article-title":"Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse","volume":"99","author":"Hubmann","year":"2014","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3109\/10428194.2013.840776","article-title":"Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse","volume":"55","author":"Jain","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: Principles, approaches, and laboratory aspects","volume":"17","author":"Hochhaus","year":"2003","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1182\/bloodadvances.2022009379","article-title":"Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study","volume":"7","author":"Scott","year":"2023","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Madaci, L., Farnault, L., Abbou, N., Gabert, J., Venton, G., and Costello, R. (2023). Impact of Next-Generation Sequencing in Diagnosis, Prognosis and Therapeutic Management of Acute Myeloid Leukemia\/Myelodysplastic Neoplasms. Cancers, 15.","DOI":"10.3390\/cancers15133280"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1080\/10428194.2020.1762884","article-title":"Wilms\u2019 tumor 1 gene in hematopoietic malignancies: Clinical implications and future directions","volume":"61","author":"Luo","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2020.260133","article-title":"Minimal residual disease monitoring in acute myeloid leukemia with non-A\/B\/D NPM1 mutations by digital polymerase chain reaction: Feasibility and clinical use","volume":"106","author":"Lesieur","year":"2021","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.13038","article-title":"Quantification of rare NPM1 mutation subtypes by digital PCR","volume":"167","author":"Bacher","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jmoldx.2021.05.001","article-title":"Double Drop-Off Droplet Digital PCR: A Novel, Versatile Tool for Mutation Screening and Residual Disease Monitoring in Acute Myeloid Leukemia Using Cellular or Cell-Free DNA","volume":"23","author":"Rausch","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The present and future of measurable residual disease testing in acute myeloid leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1007\/s00277-024-06008-z","article-title":"Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yoest, J.M., Shirai, C.L., and Duncavage, E.J. (2020). Sequencing-based measurable residual disease testing in acute myeloid leukemia. Front. Cell Dev. Biol., 8, Available online: https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2020.00249\/full.","DOI":"10.3389\/fcell.2020.00249"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrg.2017.117","article-title":"Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations","volume":"19","author":"Salk","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24922","article-title":"Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia","volume":"93","author":"Gaksch","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Lee, J.-M., Park, S., Hwang, I., Kang, D., Cho, B.S., Kim, H.-J., Ahn, A., Kim, M., and Kim, Y. (2022). FLT3-ITD Measurable Residual Disease Monitoring in Acute Myeloid Leukemia Using Next-Generation Sequencing. Cancers, 14.","DOI":"10.3390\/cancers14246121"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Colmenares, R., \u00c1lvarez, N., Barrio, S., Mart\u00ednez-L\u00f3pez, J., and Ayala, R. (2022). The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies. Cancers, 14, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/35267616\/.","DOI":"10.20944\/preprints202201.0366.v1"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40246-019-0220-8","article-title":"Next-generation sequencing in liquid biopsy: Cancer screening and early detection","volume":"13","author":"Chen","year":"2019","journal-title":"Hum. Genom."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1164017","DOI":"10.3389\/fonc.2023.1164017","article-title":"Liquid biopsies and minimal residual disease in myeloid malignancies","volume":"13","author":"Allam","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102978","DOI":"10.1016\/j.critrevonc.2020.102978","article-title":"Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)","volume":"151","author":"Rolfo","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.blre.2016.02.003","article-title":"FDG-PET imaging in hematological malignancies","volume":"30","author":"Valls","year":"2016","journal-title":"Blood Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13550-017-0326-8","article-title":"Early assessment of response to induction therapy in acute myeloid leukemia using 18F-FLT PET\/CT","volume":"7","author":"Han","year":"2017","journal-title":"EJNMMI Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.leukres.2010.06.010","article-title":"Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging","volume":"35","author":"Vanderhoek","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_76","unstructured":"(2025, September 09). Study Details|NCT02392429|FLT PET\/CT in Measuring Response in Patients with Previously Untreated Acute Myeloid Leukemia|ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02392429."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"890871","DOI":"10.3389\/fonc.2022.890871","article-title":"MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?","volume":"12","author":"Bernardi","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ong, S.Y., Tan Si Yun, M., Abdul Halim, N.A., Christopher, D., Jen, W.Y., Gallardo, C., Tan Hwee Yim, A., Woon, Y.K., Ng, H.J., and Ooi, M. (2022). Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine. Cancers, 14.","DOI":"10.3390\/cancers14153576"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ajh.24782","article-title":"Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia","volume":"92","author":"Ragon","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/ajh.27087","article-title":"Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel","volume":"98","author":"Ravandi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"WaWalter","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: Time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-021-00471-x","article-title":"Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation","volume":"11","author":"Jentzsch","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-021-00479-3","article-title":"Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: A study by the acute leukemia working party","volume":"11","author":"Gilleece","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1182\/bloodadvances.2022007168","article-title":"Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs. the second remission","volume":"6","author":"Jentzsch","year":"2022","journal-title":"Blood Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction Minimal Residual Disease Predicts Outcome and Benefit from Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with NPM1 Mutation","volume":"35","author":"Balsat","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41375-020-0780-6","article-title":"Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?","volume":"34","author":"Venditti","year":"2020","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/leu.2014.173","article-title":"Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia with Genomic Evidence of Residual Disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","article-title":"Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: A retrospective and prospective analysis","volume":"10","author":"Chang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): An open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","article-title":"Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS","volume":"7","author":"Loke","year":"2023","journal-title":"Blood Adv."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1039\/C5AN01836F","article-title":"Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood","volume":"141","author":"Jackson","year":"2016","journal-title":"Analyst"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT","volume":"105","author":"Dholaria","year":"2020","journal-title":"Haematologica"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:54:51Z","timestamp":1772708091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medsci14010123"],"URL":"https:\/\/doi.org\/10.3390\/medsci14010123","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}